SCHEMBL21370549

SCHEMBL21370549

CC[Si](CC)(CC)Oc1ccc(/C=C/c2cc(O[Si](CC)(CC)CC)cc(O[Si](CC)(CC)CC)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 6/20 0.52
CYP1B1 Q16678 6/20 0.52
NQO2 P16083 5/20 0.52
ESR1 P03372 4/20 0.52
TTR P02766 4/20 0.52
AHR P35869 3/20 0.52
CYP1A2 P05177 3/20 0.52
ABL1 P00519 2/20 0.52
ABCB1 P08183 2/20 0.52
ALOX5 P09917 2/20 0.52
BCR P11274 2/20 0.52
CYP19A1 P11511 2/20 0.52
PTGS2 P35354 2/20 0.52
TUBB4A P04350 1/20 0.52
TUBB P07437 1/20 0.52
TUBA3C P0DPH7 1/20 0.52
TUBA1B P68363 1/20 0.52
TUBA4A P68366 1/20 0.52
TUBB4B P68371 1/20 0.52
TUBB3 Q13509 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21370552 0.90 PTGS2 (0.53) CYP1A1CYP1B1NQO2ESR1TTR
SCHEMBL21370547 0.88 CYP1A1 (0.60) CYP1A1CYP1B1NQO2ESR1TTR
SCHEMBL21370604 0.85 TTR (0.70) CYP1A1CYP1B1NQO2ESR1TTR
SCHEMBL21370626 0.84 KMT2A (0.52) CYP1A1CYP1B1NQO2ESR1TTR
SCHEMBL21370554 0.82 KMT2A (0.50) CYP1A1CYP1B1NQO2ESR1TTR
SCHEMBL21356554 0.79 CYP1A1 (0.57) CYP1A1CYP1B1NQO2ESR1TTR
SCHEMBL21370600 0.79 KMT2A (0.48) TTRAHRKDM4EMEN1MAPT
SCHEMBL9375950 0.76 ALDH1A1 (0.52) KDM4EMEN1MAPTKMT2ALMNA
SCHEMBL5888608 0.76 CHRNA7 (0.46) CYP1A2KDM4EMEN1MAPTKMT2A
SCHEMBL21370548 0.75 CYP1A1 (0.52) CYP1A1CYP1B1NQO2ESR1TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365208-B2 Silylated derivatives of resveratrol and the use thereof in neurodegenerative, neurological or inflammatory diseases CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2022-06-21 US disclosed
US-20190284213-A1 SILYLATED DERIVATIVES OF RESERVATROL AND THE USE THEREOF IN NEURODEGENERATIVE, NEUROLOGICAL OR INFLAMMATORY DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11365208-B2 Silylated derivatives of resveratrol and the use thereof in neurodegenerative, neurological or inflammatory diseases SNCA, SIRT1, SIRT5 CYP1A1 2689/4885CYP1B1 3037/4885NQO2 688/4885
US-20190284213-A1 SILYLATED DERIVATIVES OF RESERVATROL AND THE USE THEREOF IN NEURODEGENERATIVE, NEUROLOGICAL OR INFLAMMATORY DISEASES SIRT1, SIRT3, SIRT2 CYP1A1 2022/4885CYP1B1 2129/4885NQO2 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.